Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W. Roloff, George Yaghmour, Amy Zhang et al.|Journal of Clinical Oncology|2024Cited by 36
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALLIbrahim Aldoss, Betsy Blunk, Gregory W. Roloff et al.|Blood Advances|2024Cited by 12
Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysisYannis K. Valtis, Karamjeet Sandhu, Rawan Faramand et al.|Blood|2025Cited by 2
KMT2Ar Adversely Impacts Brexucabtagene Autoleucel (Brexu-cel) Outcome in Adults with Relapsed/ Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia.Abdullah Ladha, Caspian Oliai, Virginia Tan et al.|Transplantation and Cellular Therapy|2025Cited by 1
Real-world toxicity of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemiaNoam E. Kopmar, Katherine C. Sutherland, Ted Gooley et al.|Blood Immunology & Cellular Therapy|2025Cited by 1